Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504166 · ClinicalTrials.gov registry record · Phase 4
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
A Phase 4 study of Osteoporosis and Osteopenia, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT00504166 is a Phase 4 study of Osteoporosis and Osteopenia that has completed, run by University of California, San Francisco. The registered enrollment target is 53 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00504166, a Phase 4 study of Osteoporosis and Osteopenia, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as compared to placebo
Conditions Studied
Interventions
- DRUG alendronate sodium
- OTHER placebo comparator
Study Locations (1)
California
- University of California Department of Radiology - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00504166
The ClinicalTrials.gov registry entry for NCT00504166 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which alendronate sodium is the first listed.
NCT00504166 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00504166 about?
NCT00504166 is a clinical study titled "Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women". The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as compared to placebo
What is the current status of trial NCT00504166?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 53 participants. The study started on 2006-02. Estimated completion is 2009-04.
What conditions does trial NCT00504166 study?
This clinical trial studies the following conditions: Osteoporosis, Osteopenia.
What interventions are being tested in trial NCT00504166?
The interventions under investigation include: alendronate sodium (DRUG), placebo comparator (OTHER).
Who is sponsoring clinical trial NCT00504166?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00504166 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.